Hepatitis C - Pipeline Review, H2 2017

Date: September 19, 2017
Pages: 448
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: HE5876B7CC2EN
Leaflet:

Download PDF Leaflet

Hepatitis C - Pipeline Review, H2 2017
Hepatitis C - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 20, 16, 1, 50, 47 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 21 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hepatitis C - Overview
Hepatitis C - Therapeutics Development
Hepatitis C - Therapeutics Assessment
Hepatitis C - Companies Involved in Therapeutics Development
Hepatitis C - Drug Profiles
Hepatitis C - Dormant Projects
Hepatitis C - Discontinued Products
Hepatitis C - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Hepatitis C, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hepatitis C - Pipeline by AbbVie Inc, H2 2017
Hepatitis C - Pipeline by AIMM Therapeutics BV, H2 2017
Hepatitis C - Pipeline by Akshaya Bio Inc, H2 2017
Hepatitis C - Pipeline by Amarillo Biosciences Inc, H2 2017
Hepatitis C - Pipeline by Amarna Therapeutics BV, H2 2017
Hepatitis C - Pipeline by ARA Healthcare Pvt Ltd, H2 2017
Hepatitis C - Pipeline by Aviragen Therapeutics Inc, H2 2017
Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017
Hepatitis C - Pipeline by Beta Pharma Inc, H2 2017
Hepatitis C - Pipeline by Biocad, H2 2017
Hepatitis C - Pipeline by Bionor Pharma AS, H2 2017
Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H2 2017
Hepatitis C - Pipeline by Biotron Ltd, H2 2017
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Hepatitis C - Pipeline by Bolder Biotechnology Inc, H2 2017
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2017
Hepatitis C - Pipeline by Cocrystal Pharma Inc, H2 2017
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by DEKK-TEC Inc, H2 2017
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Hepatitis C - Pipeline by Genecode AS, H2 2017
Hepatitis C - Pipeline by GeneCure LLC, H2 2017
Hepatitis C - Pipeline by Gilead Sciences Inc, H2 2017
Hepatitis C - Pipeline by GinkgoPharma Co Ltd, H2 2017
Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2017
Hepatitis C - Pipeline by ImmunoBiology Ltd, H2 2017
Hepatitis C - Pipeline by ImmunoClin Corp, H2 2017
Hepatitis C - Pipeline by Immunotope Inc, H2 2017
Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, H2 2017
Hepatitis C - Pipeline by JN-International Medical Corp, H2 2017
Hepatitis C - Pipeline by Johnson & Johnson, H2 2017
Hepatitis C - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Hepatitis C - Pipeline by Kineta Inc, H2 2017
Hepatitis C - Pipeline by Ligand Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by Medivir AB, H2 2017
Hepatitis C - Pipeline by Merck & Co Inc, H2 2017
Hepatitis C - Pipeline by Microbio Co Ltd, H2 2017
Hepatitis C - Pipeline by MultiCell Technologies Inc, H2 2017
Hepatitis C - Pipeline by Novalex Therapeutics Inc, H2 2017
Hepatitis C - Pipeline by Novartis AG, H2 2017
Hepatitis C - Pipeline by NovaTarg Therapeutics Inc, H2 2017
Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Hepatitis C - Pipeline by Pfenex Inc, H2 2017
Hepatitis C - Pipeline by Pfizer Inc, H2 2017
Hepatitis C - Pipeline by PharmaEssentia Corp, H2 2017
Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by Profectus BioSciences Inc, H2 2017
Hepatitis C - Pipeline by Replicor Inc, H2 2017
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2017
Hepatitis C - Pipeline by SomaGenics Inc, H2 2017
Hepatitis C - Pipeline by Sudershan Biotech Ltd, H2 2017
Hepatitis C - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017
Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017
Hepatitis C - Pipeline by Therapure Biopharma Inc, H2 2017
Hepatitis C - Pipeline by Theravectys SA, H2 2017
Hepatitis C - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2017
Hepatitis C - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Hepatitis C - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017
Hepatitis C - Pipeline by Zylacta Corp, H2 2017
Hepatitis C - Dormant Projects, H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.1), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.2), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.3), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.4), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.5), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.6), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.7), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.8), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.9), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.10), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.11), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.12), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.13), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.14), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.15), H2 2017
Hepatitis C - Dormant Projects, H2 2017 (Contd.16), H2 2017
Hepatitis C - Discontinued Products, H2 2017
Hepatitis C - Discontinued Products, H2 2017 (Contd.1), H2 2017
Hepatitis C - Discontinued Products, H2 2017 (Contd.2), H2 2017
Hepatitis C - Discontinued Products, H2 2017 (Contd.3), H2 2017
Hepatitis C - Discontinued Products, H2 2017 (Contd.4), H2 2017

LIST OF FIGURES

Number of Products under Development for Hepatitis C, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
AIMM Therapeutics BV
Akshaya Bio Inc
Amarillo Biosciences Inc
Amarna Therapeutics BV
ARA Healthcare Pvt Ltd
Aviragen Therapeutics Inc
Beijing Kawin Technology Share-Holding Co Ltd
Beta Pharma Inc
Biocad
Bionor Pharma AS
Biotest Pharmaceuticals Corp
Biotron Ltd
Boehringer Ingelheim GmbH
Bolder Biotechnology Inc
Bristol-Myers Squibb Company
Cocrystal Pharma Inc
Conatus Pharmaceuticals Inc
ContraVir Pharmaceuticals Inc
DEKK-TEC Inc
F. Hoffmann-La Roche Ltd
Genecode AS
GeneCure LLC
Gilead Sciences Inc
GinkgoPharma Co Ltd
GlaxoSmithKline Plc
ImmunoBiology Ltd
ImmunoClin Corp
Immunotope Inc
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
JN-International Medical Corp
Johnson & Johnson
Karyopharm Therapeutics Inc
Kineta Inc
Ligand Pharmaceuticals Inc
Medivir AB
Merck & Co Inc
Microbio Co Ltd
MultiCell Technologies Inc
Novalex Therapeutics Inc
Novartis AG
NovaTarg Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pfenex Inc
Pfizer Inc
PharmaEssentia Corp
Presidio Pharmaceuticals Inc
Profectus BioSciences Inc
Replicor Inc
Rodos BioTarget GmbH
SomaGenics Inc
Sudershan Biotech Ltd
TaiGen Biotechnology Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Therapure Biopharma Inc
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Vakzine Projekt Management GmbH
Vertex Pharmaceuticals Inc
WhanIn Pharmaceutical Co Ltd
Zylacta Corp
Skip to top


Hepatic Encephalopathy - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 60 pages
Hepatitis B - Pipeline Review, H2 2017 US$ 2,000.00 Nov, 2017 · 380 pages

Ask Your Question

Hepatitis C - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: